{"entity":{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","aka":[],"tldr":"The PD-L1 antibody atezolizumab shrank tumours in about a quarter of patients with advanced alveolar soft part sarcoma, with responses lasting years in a disease resistant to chemotherapy, and became the first approved treatment for this sarcoma.","summary":"Phase 2 study of 52 patients aged 2 and older with advanced alveolar soft part sarcoma treated with atezolizumab every three weeks.\n\nObjective response was 24 percent (37 percent in an updated analysis with longer follow-up), with a median duration of response of over 16 months and stable disease in most others; toxicity was typical of PD-L1 blockade and low grade.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2023","url":"https://doi.org/10.1056/NEJMoa2303383"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37672694/"}],"tags":[],"related":[],"cancers":["alveolar-soft-part-sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2303383","pmid":"37672694","authors":"Chen AP, Sharon E, O'Sullivan-Coyne G, et al.","paperType":"observational","findings":["Objective response 24 percent (37 percent with longer follow-up).","Median duration of response 16.5 months; many responses ongoing."],"whatItMeans":"Atezolizumab is the first-line systemic treatment for advanced alveolar soft part sarcoma, a rare, slow-growing but ultimately metastatic sarcoma of young adults for which chemotherapy never worked.","caveats":["Single-arm study in a rare disease; responses can take many months to appear."],"changedPractice":true,"participants":52},"route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/","neighbours":{"cancer":[{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}